Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.35 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL537494 | 1.00 | KMT2A (0.38) | KMT2AMEN1MEP1BRAPGEF4LMNA | |
| SCHEMBL909187 | 1.00 | KMT2A (0.38) | KMT2AMEN1MEP1BRAPGEF4LMNA | |
| SCHEMBL3812470 | 0.93 | MEN1 (0.34) | KMT2AMEN1MEP1BRAPGEF4LMNA | |
| SCHEMBL3809686 | 0.93 | MEN1 (0.34) | KMT2AMEN1MEP1BRAPGEF4LMNA | |
| SCHEMBL5153705 | 0.92 | ALDH1A1 (0.33) | KMT2AMEN1MEP1BRAPGEF4LMNA | |
| SCHEMBL20184269 | 0.89 | ALDH1A1 (0.44) | KMT2AMEN1LMNAALDH1A1KDM4E | |
| SCHEMBL27206070 | 0.88 | KDM4E (0.39) | KMT2AMEP1BLMNAALDH1A1KDM4E | |
| SCHEMBL30321034 | 0.87 | PRMT5 (0.42) | KMT2AMEN1LMNAALDH1A1MAPK1 | |
| SCHEMBL32681961 | 0.87 | SLC6A2 (0.37) | KMT2AMEN1MEP1BLMNAALDH1A1 | |
| SCHEMBL4795645 | 0.85 | CA2 (0.39) | KMT2AMEN1LMNACA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0485894-B1 | Methods for the preparation of semi-synthetic diastereomerically pure N-glycidyl-anthracyclines | HOECHST AG (DE) | 1999-02-03 | — | — | EP | claimed |
| EP-0485894-A1 | Semi-synthetic diastereomerically pure N-glycidyl-anthracyclines, methods for their preparation, and their use as cytostatics | BEHRINGWERKE Aktiengesellschaft (DE) | 1992-05-20 | — | — | EP | claimed |
| US-11229646-B2 | Method for treating gonorrhea with (2R)-2-({4-[(3,4-dihydro-2H-pyrano[2,3-C]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2A,5,8A-triazaacenaphthylene-3,8-dione | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2022-01-25 | — | — | US | disclosed |
| US-20200330462-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-22 | — | — | US | disclosed |
| US-10702521-B2 | Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-07-07 | — | — | US | disclosed |
| EP-3639824-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-04-22 | — | — | EP | disclosed |
| EP-3182973-B1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-09-18 | — | — | EP | disclosed |
| US-20170304301-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-26 | — | — | US | disclosed |
| EP-3182973-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2017-06-28 | — | — | EP | disclosed |
| WO-2016027249-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-02-25 | — | — | WO | disclosed |
| US-9051331-B2 | Substituted dihydro benzocycloalkyloxymethyl oxazolopyrimidinones, preparation and use thereof | SANOFI (FR) | 2015-06-09 | — | — | US | disclosed |
| WO-1995002584-A2 | PROCESS FOR MAKING HIV PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 1995-01-26 | — | — | WO | disclosed |
| WO-1994003425-A2 | CARBOSTYRIL DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIA | SYNTEX (U.S.A.) INC. (US) | 1994-02-17 | — | — | WO | disclosed |
| US-5264596-A | Isotactic poly(glycidyl nitrate) and synthesis thereof | THIOKOL CORPORATION (US) | 1993-11-23 | — | — | US | disclosed |
| EP-0518110-A2 | Process for the preparation of pure enatiomers of 4-[4-(4'-tert.butylphenyl)-2-hydroxybutoxy]-benzoic acid and its alkyl ester | Klinge Pharma GmbH (DE) | 1992-12-16 | — | — | EP | disclosed |
| US-5162494-A | ISOTACTIC POLY(GLYDICYL NITRATE) AND SYNTHESIS THEREOF | THIOKOL CORPORATION (US) | 1992-11-10 | — | — | US | disclosed |
| EP-0485894-A1 | Semi-synthetic diastereomerically pure N-glycidyl-anthracyclines, methods for their preparation, and their use as cytostatics | BEHRINGWERKE Aktiengesellschaft (DE) | 1992-05-20 | — | — | EP | disclosed |
| EP-0485099-A1 | Isotactic poly(glycidyl nitrate) and synthesis thereof | THIOKOL CORPORATION (US) | 1992-05-13 | — | — | EP | disclosed |
| EP-0467325-A2 | Carbostyril derivatives | SYNTEX (U.S.A.) INC. (US) | 1992-01-22 | — | — | EP | disclosed |
| US-5082847-A | Antiarrhythmia | SYNTEX (U.S.A.) INC. (US) | 1992-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200330462-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | NME2, NNMT, NGLY1 | KMT2A 3610/4885MEN1 1686/4885MEP1B 3033/4885 |
| US-10702521-B2 | Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones | DHPS, HSD17B11, GNE | KMT2A 2573/4885MEN1 1673/4885MEP1B 2879/4885 |
| US-11229646-B2 | Method for treating gonorrhea with (2R)-2-({4-[(3,4-dihydro-2H-pyrano[2,3-C]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2A,5,8A-triazaacenaphthylene-3,8-dione | GMPS, GNE, DHPS | KMT2A 1748/4885MEN1 2729/4885MEP1B 2735/4885 |
| US-20170304301-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | NME2, NNMT, NGLY1 | KMT2A 3610/4885MEN1 1686/4885MEP1B 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.